Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo

Trial Profile

Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Solanezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms DeNDRoN; DeNDRoN2449; EXPEDITION 3
  • Sponsors Eli Lilly
  • Most Recent Events

    • 20 Jul 2017 Results evaluating central drug target engagement (TE) and pharmacodynamic (PD) activity of solanezumab in EXPEDITION3 and comparing both to that in the pooled mild AD population from EXPEDITION and EXPEDITION 2 studies, presented at the Alzheimer's Association International Conference 2017
    • 20 Jul 2017 Results of PK/PD model development and evaluation using patient data from NCT00905372, NCT00904683, NCT01900665 trials presented at the Alzheimer's Association International Conference 2017
    • 20 Jul 2017 Results assessing the effect of Solanezumab on biomarkers of neurodegeneration in the Expedition 3 Trial, presented at the Alzheimer's Association International Conference 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top